Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma

Cancer Cell

Volumn 22, Issue 3, 2012, Pages 359-372

  Monti, Stefano ^a,e   Chapuy, Bjoern ^b   Takeyama, Kunihiko ^b,f   Rodig, Scott J ^c   Hao, Yansheng ^b   Yeda, Kelly T ^b   Inguilizian, Haig ^b   Mermel, Craig ^a   Currie, Treeve ^c,f   Dogan, Ahmet ^d   Kutok, Jeffery L ^c,f   Beroukhim, Rameen ^a   Neuberg, Donna ^b   Habermann, Thomas M ^d   Getz, Gad ^a   Kung, Andrew L ^b   Golub, Todd R ^a,b   Shipp, Margaret A ^b  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLAVOPIRIDOL; KI 67 ANTIGEN; PREDNISONE; PROTEIN P53; RITUXIMAB; TRANSCRIPTION FACTOR E2F; VINCRISTINE SULFATE;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL PROLIFERATION; COPY NUMBER VARIATION; ENZYME ACTIVITY; HUMAN; LARGE CELL LYMPHOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84866028455     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.07.014     Document Type: Article

References (66)

1. Agger K., Cloos P.A.C., Rudkjaer L., Williams K., Andersen G., Christensen J., Helin K. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 2009, 23:1171-1176.
2. Bea S., Zettl A., Wright G., Salaverria I., Jehn P., Moreno V., Burek C., Ott G., Puig X., Yang L., et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005, 106:3183-3190.
3. Beaudry V.G., Jiang D., Dusek R.L., Park E.J., Knezevich S., Ridd K., Vogel H., Bastian B.C., Attardi L.D. Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis. PLoS Genet. 2010, 6:e1001168.
4. Bernal F., Wade M., Godes M., Davis T.N., Whitehead D.G., Kung A.L., Wahl G.M., Walensky L.D. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 2010, 18:411-422.
5. Beroukhim R., Getz G., Nghiemphu L., Barretina J., Hsueh T., Linhart D., Vivanco I., Lee J.C., Huang J.H., Alexander S., et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA 2007, 104:20007-20012.
6. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
7. Booman M., Szuhai K., Rosenwald A., Hartmann E., Kluin-Nelemans H.C., de Jong D., Schuuring E., Kluin P.M. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J. Pathol. 2008, 216:209-217.
8. Bourdon J.-C., Renzing J., Robertson P.L., Fernandes K.N., Lane D.P. Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane. J. Cell Biol. 2002, 158:235-246.
9. Breunis W.B., van Mirre E., Bruin M., Geissler J., de Boer M., Peters M., Roos D., de Haas M., Koene H.R., Kuijpers T.W. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 2008, 111:1029-1038.
10. Brooks C.L., Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 2006, 21:307-315.
11. Broyde A., Boycov O., Strenov Y., Okon E., Shpilberg O., Bairey O. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am. J. Hematol. 2009, 84:338-343.
12. Calado D.P., Zhang B., Srinivasan L., Sasaki Y., Seagal J., Unitt C., Rodig S., Kutok J., Tarakhovsky A., Schmidt-Supprian M., Rajewsky K. Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 2010, 18:580-589.
13. Camilleri-Broët S., Cassard L., Broët P., Delmer A., Le Touneau A., Diebold J., Fridman W.H., Molina T.J., Sautès-Fridman C. FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. Br. J. Haematol. 2004, 124:55-62.
14. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
15. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
16. Cato M.H., Chintalapati S.K., Yau I.W., Omori S.A., Rickert R.C. Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. Mol. Cell. Biol. 2011, 31:127-137.
17. Challa-Malladi M., Lieu Y.K., Califano O., Holmes A.B., Bhagat G., Murty V.V., Dominguez-Sola D., Pasqualucci L., Dalla-Favera R. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011, 20:728-740.
18. Chen J., Kastan M.B. 5'-3'-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage. Genes Dev. 2010, 24:2146-2156.
19. Chen L., Monti S., Juszczynski P., Daley J., Chen W., Witzig T.E., Habermann T.M., Kutok J.L., Shipp M.A. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111:2230-2237.
20. Dornan D., Bheddah S., Newton K., Ince W., Frantz G.D., Dowd P., Koeppen H., Dixit V.M., French D.M. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 2004, 64:7226-7230.
21. Faber A.C., Chiles T.C. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas. Cell Cycle 2007, 6:2982-2989.
22. Friedberg J.W., Fisher R.I. Diffuse large B-cell lymphoma. Hematol. Oncol. Clin. North Am. 2008, 22:941-952. ix.
23. Fu K., Weisenburger D.D., Choi W.W., Perry K.D., Smith L.M., Shi X., Hans C.P., Greiner T.C., Bierman P.J., Bociek R.G., et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J. Clin. Oncol. 2008, 26:4587-4594.
24. Grogan T.M., Lippman S.M., Spier C.M., Slymen D.J., Rybski J.A., Rangel C.S., Richter L.C., Miller T.P. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988, 71:1157-1160.
25. Hernando E., Nahlé Z., Juan G., Diaz-Rodriguez E., Alaminos M., Hemann M., Michel L., Mittal V., Gerald W., Benezra R., et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004, 430:797-802.
26. Infantino S., Benz B., Waldmann T., Jung M., Schneider R., Reth M. Arginine methylation of the B cell antigen receptor promotes differentiation. J. Exp. Med. 2010, 207:711-719.
27. Jardin F., Jais J.-P., Molina T.-J., Parmentier F., Picquenot J.-M., Ruminy P., Tilly H., Bastard C., Salles G.-A., Feugier P., et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood 2010, 116:1092-1104.
28. Jordanova E.S., Riemersma S.A., Philippo K., Schuuring E., Kluin P.M. Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int. J. Cancer 2003, 103:393-398.
29. Kato M., Sanada M., Kato I., Sato Y., Takita J., Takeuchi K., Niwa A., Chen Y., Nakazaki K., Nomoto J., et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459:712-716.
30. Klein U., Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 2008, 8:22-33.
31. Knudsen E.S., Knudsen K.E. Tailoring to RB: tumour suppressor status and therapeutic response. Nat. Rev. Cancer 2008, 8:714-724.
32. Kwei K.A., Kung Y., Salari K., Holcomb I.N., Pollack J.R. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol. Oncol. 2010, 4:255-266.
33. Lapenna S., Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 2009, 8:547-566.
34. Lenz G., Staudt L.M. Aggressive lymphomas. N. Engl. J. Med. 2010, 362:1417-1429.
35. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., Xu W., Tan B., Goldschmidt N., Iqbal J., et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 2008, 359:2313-2323. Lymphoma/Leukemia Molecular Profiling Project.
36. Lenz G., Wright G.W., Emre N.C., Kohlhammer H., Dave S.S., Davis R.E., Carty S., Lam L.T., Shaffer A.L., Xiao W., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. USA 2008, 105:13520-13525.
37. Leu C.M., Davis R.S., Gartland L.A., Fine W.D., Cooper M.D. FcRH1: an activation coreceptor on human B cells. Blood 2005, 105:1121-1126.
38. Lohr J.G., Stojanov P., Lawrence M.S., Auclair D., Chapuy B., Sougnez C., Cruz-Gordillo P., Knoechel B., Asmann Y.W., Slager S.L., et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012, 109:3879-3884.
39. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 2009, 9:153-166.
40. Mandelbaum J., Bhagat G., Tang H., Mo T., Brahmachary M., Shen Q., Chadburn A., Rajewsky K., Tarakhovsky A., Pasqualucci L., Dalla-Favera R. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010, 18:568-579.
41. Matijasevic Z., Krzywicka-Racka A., Sluder G., Jones S.N. MdmX regulates transformation and chromosomal stability in p53-deficient cells. Cell Cycle 2008, 7:2967-2973.
42. Middendorp S., Xiao Y., Song J.Y., Peperzak V., Krijger P.H., Jacobs H., Borst J. Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood 2009, 114:2280-2289.
43. Monti S., Savage K.J., Kutok J.L., Feuerhake F., Kurtin P., Mihm M., Wu B., Pasqualucci L., Neuberg D., Aguiar R.C., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105:1851-1861.
44. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., Johnson N.A., Severson T.M., Chiu R., Field M., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
45. Nicholson T.B., Chen T., Richard S. The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation. Pharmacol. Res. 2009, 60:466-474.
46. Ofir-Rosenfeld Y., Boggs K., Michael D., Kastan M.B., Oren M. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol. Cell 2008, 32:180-189.
47. Pasqualucci L., Compagno M., Houldsworth J., Monti S., Grunn A., Nandula S.V., Aster J.C., Murty V.V., Shipp M.A., Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 2006, 203:311-317.
48. Pasqualucci L., Trifonov V., Fabbri G., Ma J., Rossi D., Chiarenza A., Wells V.A., Grunn A., Messina M., Elliot O., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 2011, 43:830-837.
49. Polager S., Ginsberg D. p53 and E2f: partners in life and death. Nat. Rev. Cancer 2009, 9:738-748.
50. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 2003, 3:781-790.
51. Salles G., de Jong D., Xie W., Rosenwald A., Chhanabhai M., Gaulard P., Klapper W., Calaminici M., Sander B., Thorns C., et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011, 117:7070-7078.
52. Sánchez-Beato M., Sánchez-Aguilera A., Piris M.A. Cell cycle deregulation in B-cell lymphomas. Blood 2003, 101:1220-1235.
53. Shangary S., Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin. Cancer Res. 2008, 14:5318-5324.
54. Shembade N., Ma A., Harhaj E.W. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010, 327:1135-1139.
55. Shipp M., Harrington D., Chairpersons, Anderson J., Armitage J., Bonadonna G., Brittinger G., Cabanillas F., Canellos G., Coiffier B., Connors J., et al. A predictive model for aggressive non-Hodgkin's lymphoma: The International NHL Prognostic Factors Project. N. Engl. J. Med. 1993, 329:987-994.
56. Shlien A., Tabori U., Marshall C.R., Pienkowska M., Feuk L., Novokmet A., Nanda S., Druker H., Scherer S.W., Malkin D. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc. Natl. Acad. Sci. USA 2008, 105:11264-11269.
57. Sola S., Xavier J.M., Santos D.M., Aranha M.M., Morgado A.L., Jepsen K., Rodrigues C.M.P. p53 interaction with JMJD3 results in its nuclear distribution during mouse neural stem cell differentiation. PLoS One 2011, 6:e18421.
58. Stegh A.H., DePinho R.A. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle 2011, 10:33-38.
59. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
60. Takagi M., Absalon M.J., McLure K.G., Kastan M.B. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005, 123:49-63.
61. Thompson S.L., Bakhoum S.F., Compton D.A. Mechanisms of chromosomal instability. Curr. Biol. 2010, 20:R285-R295.
62. Wang P., Lushnikova T., Odvody J., Greiner T.C., Jones S.N., Eischen C.M. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene 2008, 27:1590-1598.
63. Wilson N.S., Dixit V., Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 2009, 10:348-355.
64. Winter J.N., Li S., Aurora V., Variakojis D., Nelson B., Krajewska M., Zhang L., Habermann T.M., Fisher R.I., Macon W.R., et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin. Cancer Res. 2010, 16:2435-2442.
65. Yamagata K., Daitoku H., Takahashi Y., Namiki K., Hisatake K., Kako K., Mukai H., Kasuya Y., Fukamizu A. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol. Cell 2008, 32:221-231.
66. Young K.H., Leroy K., Møller M.B., Colleoni G.W.B., Sánchez-Beato M., Kerbauy F.R., Haioun C., Eickhoff J.C., Young A.H., Gaulard P., et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008, 112:3088-3098.